home / stock / innpf / innpf news

INNPF News and Press, Innovative Properties Inc From 09/06/22

Stock Information
Company Name: Innovative Properties Inc
Stock Symbol: INNPF
Market: OTC
Website: innocanpharma.com
Menu
INNPF INNPF Quote INNPF Short INNPF News INNPF Articles INNPF Message Board
Get INNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
INNPF - Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabin...
INNPF - Innocan Pharma reports Q2 results

Innocan Pharma press release ( OTCQB:INNPF ): Q2 net loss for Q2-22 - $1.8M compared to Q2-21 of $1.0M, an increase of approximately 75% from the corresponding quarter. Revenue of $0.42M (+366.7% Y/Y). For further details see: Innocan Pharma reports Q2 results ...

INNPF - Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operatin...

INNPF - Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection Pain and well-being scores improved following treatment Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) ...
INNPF - Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technology This is compared to 6.5-20% bioavailability in humans when administered orally Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corpor...

INNPF - Innocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", c...

INNPF - Innocan Pharma Files PCT Patent Application for Diabetic Symptoms

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of diabetic sympt...
INNPF - Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 12, 2022) -  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has appointed Nissim Vasilevski as Analytical Chemist. In this role, Mr. Vasilevski will ...

INNPF - Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In th...

INNPF - Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 24, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful preclinical trials in dogs with osteoarthritis. A case entailing the clinical condition of G...
Previous 10 Next 10